Brief: Simcere Pharmaceutical Posts FY Profit Attributable Rmb1,344 Million
25/03/2026 15:29
March 25 (Reuters) - Simcere Pharmaceutical 2096.HK: FY PROFIT ATTRIBUTABLE RMB1,344 MILLION Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660